We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Takes First Step Toward Revoking ANDA
Kite Pharma Wins Breakthrough Therapy Designation From FDA for KTE-C19
Merck KGaA, Threshold Cancer Drug Falls Short in Phase 3
Xbiotech’s Xilonix Meets Primary Endpoints for Advanced Colorectal Cancer Read More
The UK’s Medicines and Healthcare products Regulatory Agency has given its blessing to AstraZeneca's Tagrisso as part of the Early Access to Medicines Scheme. Read More
Given safety risks and weaker evidence in some patients, the FDA says it is questioning whether positive findings reported for Teva’s asthma drug reslizumab are enough to warrant approval. Read More
The Department of Justice has netted $96 million from the pharmaceutical industry in settlements and judgments from civil cases involving fraud and false claims against the government in the fiscal year ending Sept. 30. Read More
Pfizer to Close Neusentis UK Development Unit
Korean Regulators Approve Samsung Bioepis Remicade Biosimilar
FDA Approves Sun Pharma’s Generic Gleevec
Mundipharma Scoops Up Merck’s Glaucoma Portfolio
Sanofi Launches Injectable Polio Vaccine in India
TaiGen’s Community-Acquired Pneumonia Treatment Succeeds in Phase 3 Read More
Following a safety review, the FDA has added additional warnings to the labels of SGLT2 inhibitors for diabetes because they can cause the body to produce too much acid in the blood or lead to serious urinary tract infections. Read More
Teva Pharmaceuticals is getting ready to divest assets in anticipation of regulatory objections to its purchase of Allergan’s generics division, according to a corporate filing. Read More